Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Pyxis Oncology Inc (PYXS)

Pyxis Oncology Inc (PYXS)
0.9371 -0.0428 (-4.37%) 14:44 ET [NASDAQ]
0.9186 x 200 0.9373 x 100
Realtime by (Cboe BZX)
0.9186 x 200 0.9373 x 100
Realtime 0.9707 -0.0092 (-) 09:01 ET
Quote Overview for Tue, Apr 1st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
0.9100
Day High
0.9799
Open 0.9799
Previous Close 0.9799 0.9799
Volume 321,108 321,108
Avg Vol 473,085 473,085
Stochastic %K 23.60% 23.60%
Weighted Alpha -73.15 -73.15
5-Day Change -0.2350 (-20.43%) -0.2350 (-20.43%)
52-Week Range 0.9107 - 6.1800 0.9107 - 6.1800
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 60,352
  • Shares Outstanding, K 61,590
  • Annual Sales, $ 16,150 K
  • Annual Income, $ -77,330 K
  • EBIT $ -69 M
  • EBITDA $ -72 M
  • 60-Month Beta 1.12
  • Price/Sales 4.04
  • Price/Cash Flow N/A
  • Price/Book 0.52
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.02
  • Most Recent Earnings $-0.32 on 03/18/25
  • Next Earnings Date 05/13/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Options Overview Details

View History
  • Implied Volatility 454.84% ( -198.02%)
  • Historical Volatility 76.40%
  • IV Percentile 95%
  • IV Rank 50.52%
  • IV High 889.90% on 03/17/25
  • IV Low 10.70% on 07/15/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 33
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 6,128
  • Open Int (30-Day) 5,788

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.29
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.32
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -383.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9107 +0.47%
on 04/01/25
Period Open: 1.1900
1.2440 -26.45%
on 03/24/25
-0.2750 (-23.11%)
since 02/28/25
3-Month
0.9107 +0.47%
on 04/01/25
Period Open: 1.5600
1.8200 -49.73%
on 01/07/25
-0.6450 (-41.35%)
since 12/31/24
52-Week
0.9107 +0.47%
on 04/01/25
Period Open: 4.7900
6.1800 -85.19%
on 04/03/24
-3.8750 (-80.90%)
since 04/01/24

Most Recent Stories

More News
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

PYXS : 0.9371 (-4.37%)
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PYXS : 0.9371 (-4.37%)
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

PYXS : 0.9371 (-4.37%)
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

PYXS : 0.9371 (-4.37%)
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial

PYXS : 0.9371 (-4.37%)
Pyxis Oncology Prioritizes Development of Lead Asset PYX-201 Following Promising Phase 1 Results

Pyxis Oncology prioritizes development of PYX-201, an antibody-drug conjugate showing promise in treating solid tumors, including HNSCC.Quiver AI SummaryPyxis Oncology, Inc. is reallocating its resources...

PYXS : 0.9371 (-4.37%)
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201

PYXS : 0.9371 (-4.37%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.5353 (-2.67%)
PYXS : 0.9371 (-4.37%)
RPTX : 1.0200 (+3.46%)
IMRX : 1.5000 (-1.32%)
CVM : 0.2195 (-4.73%)
ONC.TO : 0.78 (-1.27%)
Stocks Rise Before the Open With U.S. Economic Data in Focus, Nvidia Slips on Disappointing Forecast

December S&P 500 E-Mini futures (ESZ24) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.09% this morning as investors looked ahead to a raft of U.S. economic data that could provide...

TGT : 103.82 (-0.52%)
EVTC : 36.88 (+0.30%)
NVDA : 108.11 (-0.25%)
DE : 475.78 (+1.37%)
PYXS : 0.9371 (-4.37%)
INTU : 610.01 (-0.65%)
SNOW : 147.80 (+1.12%)
JD-.LN : 69.400 (+2.21%)
NQZ24 : 20,947.98s (-0.78%)
FN : 194.39 (-1.58%)
CPRT : 56.72 (+0.23%)
QCOM : 151.33 (-1.48%)
Pyxis Oncology Reports Promising Phase 1 Clinical Data for PYX-201 in Multiple Solid Tumors and Announces Collaboration with Merck to Evaluate Combination Therapy

PYX-201 shows promising efficacy and safety in solid tumors, with expansion trials set to begin in 2025.Quiver AI SummaryPyxis Oncology announced positive preliminary results from a Phase 1 dose escalation...

PYXS : 0.9371 (-4.37%)

Business Summary

Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 1.0967
2nd Resistance Point 1.0734
1st Resistance Point 1.0266
Last Price 0.9371
1st Support Level 0.9565
2nd Support Level 0.9332
3rd Support Level 0.8864

See More

52-Week High 6.1800
Fibonacci 61.8% 4.1671
Fibonacci 50% 3.5453
Fibonacci 38.2% 2.9236
Last Price 0.9371
52-Week Low 0.9107

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trading Volatility: How to Use IV Rank & Percentile for Smarter Options Strategies